SGLT2is linked to lower risk of kidney stones
In a recent study Paik, 2024 looked at the risk of kidney stones in patients with type 2 diabetes on SGLT2is, and compared them to patients on alternative drugs for diabetes.
Why is this important?
Type 2 diabetes (DM2) is associated with an increased risk of kidney stones. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) might lower the risk of kidney stones by altering urine composition. However, no studies have investigated the association between SGLT2i use and kidney stone risk. This is why this study was done.
What did the study show?
A total of 716,406 adults with DM2 initiating an SGLT2i or a GLP-1RA or a DPP4i were included.
Over a median follow-up of 192 days, the risk of kidney stones was lower in patients initiating an SGLT2i than among those initiating a GLP-1RA (14.9 vs 21.3 events per 1000 person-years) or a DPP4i (14.6 vs 19.9 events per 1000 person-years).
The association between SGLT2i use and kidney stone risk was similar by sex, race and ethnicity, history of chronic kidney disease (CKD), and obesity. The magnitude of the risk reduction with SGLT2i use was larger among adults aged younger than 70 years vs aged 70 years or older.
How does this affect you?
These findings suggest that in patients with DM2, SGLT2i use may lower the risk of kidney stones compared with alternative drugs (GLP-1RAs or DPP4is). This may help inform decision-making when prescribing glucose-lowering agents for patients who may be at risk for developing kidney stones.
Last Reviewed on 26 June 2024
